Summit Therapeutics to Present at the Needham Healthcare Conference
March 30 2017 - 7:00AM
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and Clostridium difficile infection, announces
that Mr. Glyn Edwards, Chief Executive Officer, will present at the
Needham Healthcare Conference, 5 April 2017 at 11:20am EDT in New
York City.
A live audio webcast of the presentation will be
available through the Investors section on the Company’s website,
www.summitplc.com. A replay of the webcast will be available soon
after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
For more information, please contact:
Summit
Therapeutics |
|
|
Glyn Edwards / Richard
Pye (UK office) |
|
Tel: +44 (0)1235 443
951 |
Erik Ostrowski /
Michelle Avery (US office) |
|
+1 617 225 4455 |
|
|
|
Cairn Financial
Advisers LLP |
|
|
(Nominated
Adviser) |
|
|
Liam Murray / Tony
Rawlinson |
|
Tel: +44 (0)20 7213
0880 |
|
|
|
N+1
Singer |
|
|
(Broker) |
|
|
Aubrey Powell / Jen
Boorer |
|
Tel: +44 (0)20 7496
3000 |
|
|
|
MacDougall
Biomedical Communications |
|
|
(US media contact) |
|
Tel: +1 781 235
3060 |
Karen Sharma |
|
ksharma@macbiocom.com |
|
|
|
Consilium
Strategic Communications |
|
|
(Financial public
relations, UK) |
|
Tel: +44 (0)20 3709
5700 |
Mary-Jane Elliott / Sue
Stuart / |
|
summit@consilium-comms.com |
Jessica Hodgson /
Lindsey Neville |
|
|
|
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Apr 2023 to Apr 2024